Peldacyn Drug Interactions

Capsule: Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
Antagonism in vitro has been observed between clindamycin and erythromycin. Due to possible clinical significance the two medicinal products should not be administered concurrently.
Clindamycin is metabolised predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin. Therefore, inhibitors of CYP3A4 and CYP3A5 may reduce clindamycin clearance and inducers of these isoenzymes may increase clindamycin clearance. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.
In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYPC19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4. Therefore, clinically important interactions between clindamycin and co-administered drugs metabolised by these CYP enzyme are unlikely.
Cross-resistance between clindamycin and lincomycin has been observed.
Vitamin K antagonists: Increased coagulation tests (PT/INR) and/or bleeding, have been reported in patients with clindamycin in combination with a vitamin K antagonists (e.g. warfarin, acenocoumarol and fluindione).
Coagulation tests, therefore, should be frequently monitored in patients treated with Vitamin K antagonists.
Solution for Injection: Clindamycin may enhance the action of peripheral muscle relaxant eg, suxametonium chloride, tubocurarine chloride, therefore, it should be used with caution in patients receiving such agents.
Antagonism has been demonstrated between clindamycin and erythromycin in vitro, therefore, the 2 drugs should not be administered concurrently.